Ralaniten triacetate

拉拉尼汀三乙酸酯

Ralaniten triacetate

R655532-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7. In Vitro Ralaniten triacetate (EPI-506) targets the N-terminal domain of the androgen receptor (AR), and is used for metastatic castration-resistant prostate cancer (mCRPC) research. EPI-506 is a first-in-class, highly-specific small molecule that binds to a novel target on the AR, the N-terminal domain (NTD) and directly inhibits AR transcriptional activity by blocking the interaction of the AR with transcriptional proteins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ralaniten triacetate（EPI-506）是 Ralaniten 的原制剂，是第一类口服活性雄激素受体（AR）N-末端结构域（NTD）抑制剂。Ralaniten triacetate 对全长和抗药性相关的 AR 种类都有活性，包括

1637573-04-6(DMSO)

C27H33ClO8

521 g/mol

CC(=O)OCC(COC1=CC=C(C=C1)C(C)(C)C2=CC=C(C=C2)OCC(CCl)OC(=O)C)OC(=O)C